Researchers question traditional efficacy trial model

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/moneybusinessimages)
(Image: iStock/moneybusinessimages)
According to a recent study, traditional efficacy trials have limited applicability in everyday clinical practice – an issue which researchers say needs to be amended.

As part of their research, Professors Jorgen Vestbo and Ashley Woodcock from The University of Manchester's School of Biological Sciences conducted an effectiveness and safety trial of fluticasone furoate-vilanterol to manage COPD.

Their report, Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice, was published​ in the New England Journal of Medicine.

According to the researchers, instead of using a traditional randomized cohort, the new study used representative patients who were already receiving care from a general practitioner (GP). In addition to providing the patient pool, the GPs continued administering the patients’ usual care which was built into the trial – basing the study in a real clinical environment.

In Manchester we have a strong interest in drug evaluation and respiratory medicine and we wanted to make use of a real-time combined electronic health record linking primary and secondary care for evaluating treatment in everyday practice​,” Vestbo, one of the study’s lead researchers, told Outsourcing-Pharma.com.

Additionally, GSK was in the registration phase of a new combined ICS/LABA (Relvar/Breo) and the researchers said they were “aware that there is a need for showing effectiveness and not just efficacy for new drugs​.”

As per the study’s results, Vestbo said it revealed “First, that a randomized trial of a non-registered medication was feasible in an everyday setting where patients were unselected and were not handled as patients are in an efficacy trial​,” and the new combination drug was more efficient than the usual care selected by GPs in reducing moderate and severe exacerbations of COPD.

Ultimately, Vestbo said that traditional trials (efficacy trials) will always be needed to test what a drug can do. However, he concluded, “contrary to the present situation, we need more studies to show what a drug actually does do when used by real patients and not just in selected trial participants​.”

Related news

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Related suppliers

Follow us

Products

View more

Webinars